The Latest Breaking News from RAD

Following a better-than-expected September job report, the Fed is expected to maintain its hawkish stance in the coming months. Amid increasing recession fears, the bear market might remain. Therefore, we think it could be wise to steer clear of fundamentally weak stocks Bed Bath & Beyond (BBBY) and Rite Aid…

An ageing population and rising healthcare expenditure due to increased awareness among the masses are expected to boost demand for drugstore products. On the other hand, the stock market is experiencing heightened volatility amid the ongoing macroeconomic challenges. While we think investors should buy drugstore stock CVS Health (CVS), fundamentally…

Rite Aid (RAD) shares soared last week after the company reported stronger-than-expected first-quarter revenue growth and issued an upbeat sales forecast. However, given the company’s increasing losses and projected interest rate hikes, is it worth buying the stock now? Let’s find out.

Rite Aid Corp (NYSE:RAD) has reported Q1 FY23 sales of 6.01 billion, down 2.4% Y/Y, beating the consensus of $5.75 billion.  The company reported an EPS loss of $(0.60) compared to an income of $0.38 a year ago, driven by non-cash impairment charges and cycling prior-year COVID vaccination benefit. Retail Pharmacy Segment…

Heritage Cannabis Holdings Corp. (OTCQX: HERTF) (CSE:CANN) has signed a definitive agreement for the supply of its products to a major LP for sale on its medical platform.

Whether its jerk, rice and peas or curry goat, the city is brimming with great Caribbean food

Leading pharmaceutical retailer Rite Aid (RAD) shares jumped last week thanks to its stronger-than-expected fourth-quarter revenue growth driven by an increase in same-store and pharmacy sales. Although the company’s strategic initiatives to boost membership should bode well for the stock, its struggling Elixir business and expanding losses could lead to…

Rite Aid (NYSE:RAD) reported its Q4 earnings results on Thursday, April 14, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Rite Aid missed estimated earnings by 191.07%, reporting an EPS of $-1.63 versus an estimate of $-0.56.

Rite Aid Corp (NYSE:RAD) has reported Q4 FY22 sales of 6.06 billion, +2.5% Y/Y, beating the consensus of $5.95 billion. The Company reported an EPS loss of $(1.63) compared to $(0.78) a year ago. The growth is driven by growth in the Retail Pharmacy, partially offset by a decline in the Pharmacy…